BACKGROUND: Since July 2010 Ozurdex® is approved in Germany for treatment of macular edema from retinal vein occlusion (RVO). The objective of this observational study was a systemic summary and analysis of clinical experience regarding complications and side effects of intravitreal administration of dexamethasone. PATIENTS AND METHODS: In a retrospective, multicenter study conducted at 10 centers, 342 eyes with RVO were treated with intravitreal dexamethasone (Ozurdex®, Allergan). After treatment the patients were followed-up over a period of 8 months and intraoperative, perioperative and postoperative complications, such as elevated intraocular pressure and dislocation of implants were systematically recorded. RESULTS: No infections, endophthalmitis, perioperative hypotension, intraoperative lens injuries or retinal detachment occurred. Elevated intraocular pressure was the most common complication accounting for nearly 20 %. In 9 % of patients the intraocular pressure increased by more than 10 mmHg compared to baseline and in 6 patients to > 35 mmHg. In cases of known glaucoma intraocular pressure elevation was not significantly more frequent compared to non-glaucoma patients. In four cases a progression of lens opacity led to phacoemulsification and two implant dislocations in the anterior chamber required surgical repositioning in the vitreous cavity. In two cases a postinterventional macular hole was observed. CONCLUSIONS: In the clinical routine Ozurdex treatment has proven to be a therapy method with minimal side effects. In Ozurdex administration intraocular pressure elevation was observed as the most common side effect; however, this generally did not require surgical intervention. Caution is advised in patients with an anterior chamber lens and iridectomy. Macular holes as a rare complication might result from vitreous traction during the administration process. In summary, even in the clinical routine application of Ozurdex the complication rate was not higher than in registration studies.
BACKGROUND: Since July 2010 Ozurdex® is approved in Germany for treatment of macular edema from retinal vein occlusion (RVO). The objective of this observational study was a systemic summary and analysis of clinical experience regarding complications and side effects of intravitreal administration of dexamethasone. PATIENTS AND METHODS: In a retrospective, multicenter study conducted at 10 centers, 342 eyes with RVO were treated with intravitreal dexamethasone (Ozurdex®, Allergan). After treatment the patients were followed-up over a period of 8 months and intraoperative, perioperative and postoperative complications, such as elevated intraocular pressure and dislocation of implants were systematically recorded. RESULTS: No infections, endophthalmitis, perioperative hypotension, intraoperative lens injuries or retinal detachment occurred. Elevated intraocular pressure was the most common complication accounting for nearly 20 %. In 9 % of patients the intraocular pressure increased by more than 10 mmHg compared to baseline and in 6 patients to > 35 mmHg. In cases of known glaucoma intraocular pressure elevation was not significantly more frequent compared to non-glaucomapatients. In four cases a progression of lens opacity led to phacoemulsification and two implant dislocations in the anterior chamber required surgical repositioning in the vitreous cavity. In two cases a postinterventional macular hole was observed. CONCLUSIONS: In the clinical routine Ozurdex treatment has proven to be a therapy method with minimal side effects. In Ozurdex administration intraocular pressure elevation was observed as the most common side effect; however, this generally did not require surgical intervention. Caution is advised in patients with an anterior chamber lens and iridectomy. Macular holes as a rare complication might result from vitreous traction during the administration process. In summary, even in the clinical routine application of Ozurdex the complication rate was not higher than in registration studies.
Authors: Carsten H Meyer; Eduardo B Rodrigues; Stephan Michels; Stefan Mennel; Jörg C Schmidt; Hans-Martin Helb; Annette Hager; Mauricio Martinazzo; Michel E Farah Journal: J Ocul Pharmacol Ther Date: 2010-10 Impact factor: 2.671
Authors: David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi Journal: Ophthalmology Date: 2010-04-09 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Carsten H Meyer; Adrian Klein; Florian Alten; Zengping Liu; Boris V Stanzel; Hans M Helb; Christian K Brinkmann Journal: Retina Date: 2012 Nov-Dec Impact factor: 4.256
Authors: Sophie J Bakri; Colin A McCannel; Albert O Edwards; Darius M Moshfeghi Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-04-19 Impact factor: 3.117
Authors: Sofia Theodoropoulou; Abdallah A Ellabban; Robert L Johnston; Helena Cilliers; Quresh Mohamed; Ahmed B Sallam Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-11-22 Impact factor: 3.117
Authors: Carsten H Meyer; Zengping Liu; Christian K Brinkmann; Eduardo B Rodrigues; Thomas Bertelmann Journal: J Ocul Pharmacol Ther Date: 2014-05-06 Impact factor: 2.671
Authors: Elena Pacella; Anna Rita Vestri; Roberto Muscella; Maria Rosaria Carbotti; Massimo Castellucci; Luigi Coi; Paolo Turchetti; Fernanda Pacella Journal: Clin Ophthalmol Date: 2013-07-16
Authors: Mehmet Ali Sekeroglu; Mustafa Alpaslan Anayol; Fatih Koc; Hakan Tirhis; Seyhan Sonar Ozkan; Pelin Yilmazbas Journal: Case Rep Ophthalmol Date: 2016-02-12